Ascentage Pharma Group International (NASDAQ:AAPG) Sees Unusually-High Trading Volume – Should You Buy?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shares saw strong trading volume on Monday . Approximately 5,275 shares were traded during mid-day trading, a decline of 25% from the previous session’s volume of 6,988 shares.The stock last traded at $18.90 and had previously closed at $18.50.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on AAPG. B. Riley Financial started coverage on Ascentage Pharma Group International in a research note on Wednesday, June 10th. They set a “buy” rating and a $45.00 price objective for the company. BTIG Research reaffirmed a “buy” rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a research report on Monday, June 15th. Raymond James Financial reiterated a “buy” rating on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. Deutsche Bank Aktiengesellschaft started coverage on shares of Ascentage Pharma Group International in a research report on Friday, April 24th. They set a “buy” rating and a $40.00 price target for the company. Finally, China Intl Cap upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, April 6th. Two equities research analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $46.43.

Ascentage Pharma Group International Trading Up 3.2%

The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.77 and a current ratio of 1.79. The firm’s 50-day moving average price is $19.37 and its 200 day moving average price is $23.25.

Institutional Trading of Ascentage Pharma Group International

Several institutional investors and hedge funds have recently bought and sold shares of the company. XY Capital Ltd lifted its holdings in Ascentage Pharma Group International by 224.2% during the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after buying an additional 12,530 shares during the last quarter. UBS Group AG increased its holdings in shares of Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after acquiring an additional 10,988 shares during the last quarter. Hsbc Holdings PLC bought a new stake in shares of Ascentage Pharma Group International in the 2nd quarter valued at approximately $391,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Ascentage Pharma Group International during the 3rd quarter valued at approximately $383,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.